Patents Represented by Attorney Lucy J. Billings
  • Patent number: 6143544
    Abstract: The invention provides a new human lysophospholipase (JHLP) and polynucleotides which identify and encode IHLP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating inflammation and disorders associated with expression of IHLP.
    Type: Grant
    Filed: June 19, 1997
    Date of Patent: November 7, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Purvi Shah, Neil C. Corley, Lynn E. Murry
  • Patent number: 6008039
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel purinergic P.sub.U2 receptor (PNR) expressed in human placenta. The present invention also provides for antisense molecules to the nucleotide sequences which encode PNR, expression vectors for the production of purified PNR, antibodies capable of binding specifically to PNR, hybridization probes or oligonucleotides for the detection of PNR-encoding nucleotide sequences, genetically engineered host cells for the expression of PNR, and diagnostic tests based on PNR-encoding nucleic acid molecules or antibodies produced against the polypeptide PNR.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: December 28, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Roger Coleman, Janice Au-Young, Susan G. Stuart, Karl J. Guegler
  • Patent number: 5994112
    Abstract: The present invention provides a novel protein tyrosine kinase (HPTYK) and polynucleotides which identify and encode HPTYK. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPTYK and a method for producing HPTYK. The invention also provides pharmaceutical compositions containing HPTYK or antagonists to HPTYK, and for the use of these compositions in the treatment of diseases associated with the expression of HPTYK. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HPTYK for the treatment of diseases associated with the expression of HPTYK. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, to hybridize to the genomic sequence or transcripts of polynucleotides encoding HPTYK or antibodies which specifically bind to HPTYK.
    Type: Grant
    Filed: October 9, 1996
    Date of Patent: November 30, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventor: Surya K. Goli
  • Patent number: 5972658
    Abstract: The present invention provides a human lung growth factor variant (LGFV) and polynucleotides which identify and encode LGFV. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding LGFV and a method for producing LGFV. The invention also provides for agonists, antibodies, or antagonists specifically binding LGFV, and their use, in the prevention and treatment of diseases associated with expression of LGFV. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding LGFV for the treatment of diseases associated with the expression of LGFV. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding LGFV.
    Type: Grant
    Filed: December 5, 1996
    Date of Patent: October 26, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Surya K. Goli, Lynn E. Murry
  • Patent number: 5955312
    Abstract: The present invention provides a human microtubule-associated protein (hLC3) and the polynucleotides which identify and encode hLC3. The invention also provides genetically engineered expression vectors, host cells, and a method for producing hLC3. The invention also provides hLC3 as well as agonists, antibodies, and antagonists of hLC3, and the use thereof for the prevention and treatment of diseases associated with the expression of hLC3. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding hLC3 for the treatment of diseases associated with the expression of hLC3. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding hLC3.
    Type: Grant
    Filed: February 24, 1997
    Date of Patent: September 21, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Surya K. Goli
  • Patent number: 5955278
    Abstract: The invention provides a human translational regulator (TRANAC) and polynucleotides which identify and encode TRANAC. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of TRANAC.
    Type: Grant
    Filed: June 5, 1997
    Date of Patent: September 21, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Phillip R. Hawkins
  • Patent number: 5935812
    Abstract: The present invention provides a polynucleotide which identifies and encodes a novel human GTP binding protein gamma-3 (HGPG) and HGPG itself. The invention provides for genetically engineered expression vectors, host cells containing the vector and a method for producing HGPG. The invention also provides a method for identifying pharmaceutical compositions inhibiting the expression and activity of HGPG and for the use of such compositions for the treatment of cancer. The invention also provides diagnostic assays which utilize the polynucleotide to hybridize with the transcripts encoding HGPG or anti-HGPG antibodies which specifically bind to HGPG in normal or diseased tissues.
    Type: Grant
    Filed: September 18, 1996
    Date of Patent: August 10, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Surya K. Goli, Lynn E. Murry
  • Patent number: 5922565
    Abstract: The present invention provides a human clathrin-associated protein (HAP19) and polynucleotides which identify and encode HAP19. The invention also provides expression vectors and host cells and a method for producing HAP19. The invention also provides antibodies or antagonists specifically binding HAP19, and their use, in the prevention and treatment of diseases associated with expression of HAP19. The invention also provides diagnostic assays.
    Type: Grant
    Filed: February 25, 1997
    Date of Patent: July 13, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Surya K. Goli
  • Patent number: 5919657
    Abstract: The present invention provides a thioredoxin-like protein (TIOP) and polynucleotides which identify and encode TIOP. The invention also provides expression vectors, host cells, agonists, antibodies, and antagonists. The invention also provides methods for treating disorders associated with expression of TIOP.
    Type: Grant
    Filed: April 9, 1997
    Date of Patent: July 6, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Purvi Shah
  • Patent number: 5885798
    Abstract: The present invention provides novel monocyte activating cytokine (MAC) and a polynucleotide encoding MAC. The invention also provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding MAC. The invention also provides for the production and use of substantially purified MAC in pharmaceutical compositions for the treatment of cancer and disease of the immune system. The invention also describes diagnostic assays which utilize the polynucleotide to hybridize with the transcripts encoding MAC and antibodies which specifically bind to MAC.
    Type: Grant
    Filed: August 28, 1996
    Date of Patent: March 23, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Roger Coleman, Janice Au-Young, Lynn E. Murry
  • Patent number: 5874285
    Abstract: The present invention provides polynucleotides which identify and encode a novel human nm23-like protein (H-nm23). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding H-nm23 and for a method for producing the protein. The invention also provides for the use of substantially purified H-nm23 for the treatment of diseases associated with the expression of H-nm23. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotides which hybridize with naturally occurring sequences encoding H-nm23 and antibodies which specifically bind to the protein.
    Type: Grant
    Filed: September 13, 1996
    Date of Patent: February 23, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Phillip R. Hawkins
  • Patent number: 5874244
    Abstract: The present invention provides a human NADH-D protein subunit (NDS) and polynucleotides which encode NDS. The invention also provides expression vectors, host cells, agonists, antisense molecules, antibodies, or antagonists. The invention also provides methods for treating disorders associated with expression of NDS.
    Type: Grant
    Filed: April 22, 1997
    Date of Patent: February 23, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Purvi Shah, Preeti Lal
  • Patent number: 5874248
    Abstract: The invention provides a human glutathione S-transferase (GSTH) and polynucleotides which identify and encode GSTH. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating and preventing disorders associated with expression of GSTH.
    Type: Grant
    Filed: August 21, 1997
    Date of Patent: February 23, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Neil C. Corley, Purvi Shah
  • Patent number: 5874224
    Abstract: The present invention provides a human growth factor receptor binding protein (GRBP) and polynucleotides which encode GRBP. The invention also provides expression vectors, host cells, agonists, antisense molecules, antibodies, or antagonists. The invention also provides methods for producing GRBP and for treating disorders associated with expression of GRBP.
    Type: Grant
    Filed: March 11, 1997
    Date of Patent: February 23, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Anthony P. Diegidio
  • Patent number: 5874535
    Abstract: The present invention provides a polynucleotide which identifies and encodes a novel human leptin receptor gene-related protein (LRGRP). The invention also provides expression vectors, host cells, agonists, and antagonists. The invention also provides methods for treating metabolic, reproductive, connective tissue and reproductive disorders.
    Type: Grant
    Filed: April 15, 1997
    Date of Patent: February 23, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Bernard Bailleul, A. Donny Strosberg, Ingrid E. Akerblom
  • Patent number: 5871965
    Abstract: The present invention provides two human guanylate binding proteins (designated collectively as HGBP) and polynucleotides which identify and encode HGBP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HGBP and a method for producing HGBP. The invention also provides for use of HGBP and agonists, antibodies, or antagonists specifically binding HGBP, in the prevention and treatment of diseases associated with expression of HGBP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HGBP for the treatment of diseases associated with the expression of HGBP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HGBP.
    Type: Grant
    Filed: October 25, 1996
    Date of Patent: February 16, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Janice Au-Young, Jennifer L. Hillman
  • Patent number: 5871964
    Abstract: The present invention provides a polynucleotide (mctl) which identifies and encodes a novel human C-type lectin (MCTL). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding MCTL. The invention also provides for the use of substantially purified MCTL and its agonists in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of MCTL. Additionally, the invention provides for the use of antisense molecules to mctl in pharmaceutical compositions for treatment of diseases associated with the expression of MCTL. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of mctl. The present invention also relates to anti-MCTL antibodies which specifically bind to MCTL.
    Type: Grant
    Filed: July 30, 1996
    Date of Patent: February 16, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Benjamin Graeme Cocks, Surya K. Goli, Jennifer L. Hillman
  • Patent number: 5869259
    Abstract: The invention provides a human carboxypeptidase inhibitor (CARIN) and polynucleotides which identify and encode CARIN. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of CARIN.
    Type: Grant
    Filed: June 9, 1997
    Date of Patent: February 9, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Preeti Lal
  • Patent number: 5869256
    Abstract: The present invention provides a human coatomer vesicle protein (HECOP) and polynucleotides which identify and encode HECOP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HECOP and a method for producing HECOP. The invention also provides the use of HECOP and antagonists specifically binding HECOP in the prevention and treatment of diseases associated with expression of HECOP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HECOP.
    Type: Grant
    Filed: February 24, 1997
    Date of Patent: February 9, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Surya K. Goli
  • Patent number: 5863766
    Abstract: The invention provides a human sigma receptor (SIGR) and polynucleotides which identify and encode SIGR. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of SIGR.
    Type: Grant
    Filed: September 12, 1997
    Date of Patent: January 26, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Neil C. Corley, Purvi Shah